Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
A phase 3 trial of Trastuzumab deruxtecan, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, now recruiting.
Overview
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06899126 by Daiichi Sankyo, with 686 participants planned, started 2025-10-24 and due to reach its primary completion in 2030-04-24. Interventions recorded: Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Shares Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSafety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Pemetrexed, Trastuzumab deruxtecan, Pembrolizumab, Small-cell lung cancer.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Daiichi Sankyo, Pemetrexed, Pembrolizumab, Small-cell lung cancer.
- TrialStudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab
Shares Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.